ResMed Dividends and Buybacks
Dividend criteria checks 4/6
ResMed is a dividend paying company with a current yield of 0.82% that is well covered by earnings.
Key information
0.8%
Dividend yield
0.4%
Buyback Yield
| Total Shareholder Yield | 1.2% |
| Future Dividend Yield | 1.0% |
| Dividend Growth | -11.4% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$2.120 |
| Payout ratio | 26% |
Recent dividend and buyback updates
Recent updates
ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Jan 24ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price
Jan 13
ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency
Jan 01ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10Compound Your Wealth With ResMed
Jul 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: RMD's dividends per share have been stable in the past 10 years.
Growing Dividend: RMD's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| ResMed Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RMD) | 0.8% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Medical Equipment) | 1.6% |
| Analyst forecast (RMD) (up to 3 years) | 1.0% |
Notable Dividend: RMD's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.42%).
High Dividend: RMD's dividend (0.82%) is low compared to the top 25% of dividend payers in the US market (4.47%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (26%), RMD's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (23.1%), RMD's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 05:03 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ResMed Inc. is covered by 56 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | ANZ Equities Pty Limited |
| David Rescott | Baird |
| Michael Polark | Baird |